Bristol-Myers Squibb (BMY.US) TYK2 inhibitors have achieved the primary endpoints in two key phase 3 clinical trials.

Bristol-Myers Squibb (BMY.US) announced today the positive results of the POETYK PsA-1 and POETYK PsA-2 trials. These two key Phase 3 clinical trials evaluated the efficacy and safety of the tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) in adult patients with active psoriatic arthritis (PsA).

Zhitong Finance56minutes ago

Schwab US Dividend Equity ETF Reverses In December: What's Going On?

Benzinga04:53

Bristol Myers Squibb's Sotyktu Shows Results in Psoriatic Arthritis Trials

BenzingaDec 23 20:00

Express News | Bristol-Myers Squibb Co: Sotyktu Was Well-Tolerated and Demonstrated Safety Consistent With Established Profile

BreakingsDec 23 19:59

Express News | Bristol-Myers Squibb Co - Phase 3 Trials Met Primary Endpoint With Significant Acr20 Response

BreakingsDec 23 19:59

Express News | Bristol Myers Squibb Announces Positive Topline Results From Two Pivotal Phase 3 Trials Evaluating Sotyktu (Deucravacitinib) in Adults With Psoriatic Arthritis

BreakingsDec 23 19:59